Innate immune cells and associated pattern recognition pathways activated by ISCOMATRIX

ISCOMATRIX is a saponin-based adjuvant system composed of saponin, cholesterol, and phospholipids that forms characteristic 40-nm cage-like structures (Maraskovsky et al., 2009). It is designed to enhance the immunogenicity of vaccine antigens by activating innate immune cells and specific pattern recognition pathways. The primary molecular mechanism involves the activation of the NLRP3 inflammasome within antigen-presenting cells, such as dendritic cells and macrophages (Wilson et al., 2014). This activation triggers the proteolytic cleavage and release of pro-inflammatory cytokines, specifically IL-1β and IL-18. Furthermore, ISCOMATRIX induces a rapid recruitment of neutrophils, monocytes, and dendritic cells to the injection site, creating an immunocompetent environment (Morelli et al., 2012). It is particularly noted for its ability to facilitate the cross-presentation of exogenous antigens via the MHC class I pathway, leading to strong CD8+ T cell responses (Sjölander et al., 1998). In addition to cellular immunity, it promotes high-titer, long-lasting antibody responses and Th1-biased cytokine profiles. While effective in clinical trials for various infectious diseases and oncology, the complexity of the innate pathways it triggers means that safety monitoring for local and systemic inflammation is essential.

Other names

ISCOMATRIX-activated pathwaysSaponin-adjuvant signalingNLRP3 inflammasome pathwayISCOMATRIX-induced innate immune response

Activation of the NLRP3 inflammasome and induction of pro-inflammatory cytokine release (IL-1β, IL-18) to enhance antigen cross-presentation and T-cell priming.